Adding Menin Inhibitor Promising in Certain AML Patients

(MedPage Today) — Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML), according to results…

Source link : https://www.medpagetoday.com/meetingcoverage/eha/116071

Author :

Publish date : 2025-06-13 18:01:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Adding Menin Inhibitor Promising in Certain AML Patients

Perseverance rover may hold secrets to newly discovered Mars volcano

Early Smartphone-Activated Bystander CPR Can Boost Survival

Related Posts

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

War Is a Global Health Catastrophe

Categories

Archives